Viemed Healthcare Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viemed Healthcare (VMD).

Price Target Range — 1 Quarters

Analyst Consensus — 2 Analysts

1Buy

1Hold

Consensus RatingHold# Analysts2Avg. Consensus PT$13Upside to Avg. PT+23.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 24, 2026	Barrington Research	—	Initiate	Outperform	$14
Aug 6, 2026	Freedom Broker	Ilya Zubkov	Downgrade	Buy→Hold	$11

Analyst Ratings News

PRO
Barrington Research Initiates Coverage On Viemed Healthcare with Outperform Rating, Announces Price Target of $14

Barrington Research initiates coverage on Viemed Healthcare (NASDAQ:VMD) with a Outperform rating and announces Price Target of $14.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Viemed Healthcare, Lowers Price Target to $9

RBC Capital analyst Frank Morgan maintains Viemed Healthcare (NASDAQ:VMD) with a Outperform and lowers the price target from $13 to $9.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For March 5, 2021

Benzinga Insights

PRO
RBC Capital Initiates Coverage On Viemed Healthcare with Outperform Rating, Announces Price Target of $13

RBC Capital analyst Anton Hie initiates coverage on Viemed Healthcare (NASDAQ:VMD) with a Outperform rating and announces Price Target of $13.

Benzinga Newsdesk

PRO
Viemed Healthcare Q1 Sales $23.8M, Up 31% YoY

Benzinga Newsdesk

Viemed Healthcare Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Viemed Healthcare Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barrington Research Initiates Coverage On Viemed Healthcare with Outperform Rating, Announces Price Target of $14

PRO
RBC Capital Maintains Outperform on Viemed Healthcare, Lowers Price Target to $9

Benzinga's Top Ratings Upgrades, Downgrades For March 5, 2021

PRO
RBC Capital Initiates Coverage On Viemed Healthcare with Outperform Rating, Announces Price Target of $13

PRO
Viemed Healthcare Q1 Sales $23.8M, Up 31% YoY

People Also Watch

People Also Watch

Viemed Healthcare Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Viemed Healthcare Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarrington Research Initiates Coverage On Viemed Healthcare with Outperform Rating, Announces Price Target of $14

PRORBC Capital Maintains Outperform on Viemed Healthcare, Lowers Price Target to $9

Benzinga's Top Ratings Upgrades, Downgrades For March 5, 2021

PRORBC Capital Initiates Coverage On Viemed Healthcare with Outperform Rating, Announces Price Target of $13

PROViemed Healthcare Q1 Sales $23.8M, Up 31% YoY

People Also Watch

People Also Watch

PRO
Barrington Research Initiates Coverage On Viemed Healthcare with Outperform Rating, Announces Price Target of $14

PRO
RBC Capital Maintains Outperform on Viemed Healthcare, Lowers Price Target to $9

PRO
RBC Capital Initiates Coverage On Viemed Healthcare with Outperform Rating, Announces Price Target of $13

PRO
Viemed Healthcare Q1 Sales $23.8M, Up 31% YoY